

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/044294 A3

(51) International Patent Classification⁷: **A61K 39/395, 38/20, A61P 35/02 // (A61K 39/395, 38:20)**

(74) Agents: **ALEXANDER, Lisa, E. et al.**; Chiron Corporation, Intellectual Property Department, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(21) International Application Number:

PCT/US2004/036958

(22) International Filing Date:

4 November 2004 (04.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/517,337	4 November 2003 (04.11.2003)	US
60/525,579	26 November 2003 (26.11.2003)	US
60/565,710	27 April 2004 (27.04.2004)	US

(71) Applicant (for all designated States except US): **CHIRON CORPORATION** [US/US]; 4560 Horton Street, Emeryville, CA 94608-2916 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LONG, Li** [CA/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **LUQMAN, Mohammad** [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **YABANNAVAR, Asha** [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **ZAROR, Isabel** [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **HURST, Deborah** [US/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US). **LOPES DE MENEZES, Daniel, E.** [PT/US]; Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
15 September 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/044294 A3

(54) Title: METHOD OF THERAPY FOR CANCERS EXPRESSING THE CD40 ANTIGEN

(57) Abstract: Methods of treating a subject for a cancer comprising neoplastic cells expressing the CD40 cell surface antigen are provided. The methods comprise combination therapy with interleukin-2 (IL-2) or biologically active variant thereof and at least one antagonist anti-CD40 antibody or antigen-binding fragment thereof. In some embodiments, these two therapeutic agents are concurrently administered as two separate pharmaceutical compositions, one containing IL-2 or biologically active variant thereof, which is administered according to a constant IL-2 dosing regimen or a two-level IL-2 dosing regimen, the other containing the antagonist anti-CD40 antibody or suitable antigen binding fragment thereof, which is administered according to a weekly dosing regimen, or alternatively is dosed once every two, three, or four weeks. Administering of these two agents together potentiates their effectiveness in promoting a positive therapeutic response. The methods find use in treating CD40-expressing cancers, including B-cell related cancers and solid tumors.